Antimicrobial Agents and Chemotherapy, March 2001, p. 936-937, Vol. 45, No. 3
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.3.936-937.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
NYCOM Microbiology and Immunodiagnostic Laboratory of the New York Institute of Technology, Old Westbury, New York 11568;1 Division of Infectious Diseases, Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, New York 105952; and Schering-Plough Research Institute, Kenilworth, New Jersey 070733
Received 2 June 2000/Returned for modification 3 October 2000/Accepted 21 November 2000
The MICs of evernimicin at which 90% of Borrelia burgdorferi patient isolates were inhibited ranged from 0.1 to 0.5 µg/ml. Evernimicin was as effective as ceftriaxone against B. burgdorferi in a murine model of experimental Lyme disease. As assessed by culturing the urinary bladders of infected C3H mice, no live Borrelia isolates were recoverable following antibiotic treatment.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |